BioWorld1h
Novocure’s tumor treating fields land FDA approval for lung cancer
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
Targeted Oncology6h
FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...
The American Journal of Managed Care8h
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Medscape8h
The Long Shots: When Patients Defy All Odds
Oncologists never know which patients with dire prognoses will be among the rare, but real responders. The few who defy all ...
FierceBiotech9h
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Targeted Oncology9h
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Yahoo Finance12h
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel ...
The Pharma Letter12h
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer.
The Lancet13h
Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer
Notably, 370 (83%) participants had squamous cell carcinoma, 215 (48%) had received previous chemoradiotherapy, 116 (26%) had a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of ...
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
bovnews23h
Novocure’s (NVCR) Optune Lua Approval Sparks Market Surge
In a significant development for cancer treatment, Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administration (FDA) has approved its innovative device, Optune Lua®, for use in ...